Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Israeli

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Gut|August 16, 2005
Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel diseaseE Israeli, I Grotto, B Gilburd, et al.
Transplantation Proceedings|June 17, 2000
The course of hepatitis B virus after liver transplantationE Israeli, A Eid, Y Ilan, et al.
Transplantation Proceedings|September 7, 2001
Combination therapy for hepatitis C virus reinfection after orthoptic liver transplantationE Israeli, E Galun, A Eid, et al.
The Israel Medical Association Journal : IMAJ|May 10, 2001
Can West Nile virus outbreaks be controlled?S Lustig, M Halevy, P Fuchs, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 29, 1997
Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibodyA Waisman, P J Ruiz, E Israeli, et al.
Alimentary Pharmacology & Therapeutics|August 17, 2002
Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's diseaseR W Stockbrügger, E J Schoon, S Bollani, et al.
Clinical and Experimental Immunology|April 8, 2015
Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trialE Israeli, E Goldin, S Fishman, et al.
Alimentary Pharmacology & Therapeutics|December 2, 2010
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximabU Kopylov, G J Mantzaris, K H Katsanos, et al.
Human Genetics|September 1, 2018
Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel diseaseE R Schiff, M Frampton, N Ben-Yosef, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Gut|August 16, 2005
Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel diseaseE Israeli, I Grotto, B Gilburd, et al.
Transplantation Proceedings|June 17, 2000
The course of hepatitis B virus after liver transplantationE Israeli, A Eid, Y Ilan, et al.
Transplantation Proceedings|September 7, 2001
Combination therapy for hepatitis C virus reinfection after orthoptic liver transplantationE Israeli, E Galun, A Eid, et al.
The Israel Medical Association Journal : IMAJ|May 10, 2001
Can West Nile virus outbreaks be controlled?S Lustig, M Halevy, P Fuchs, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 29, 1997
Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibodyA Waisman, P J Ruiz, E Israeli, et al.
Alimentary Pharmacology & Therapeutics|August 17, 2002
Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's diseaseR W Stockbrügger, E J Schoon, S Bollani, et al.
Clinical and Experimental Immunology|April 8, 2015
Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trialE Israeli, E Goldin, S Fishman, et al.
Alimentary Pharmacology & Therapeutics|December 2, 2010
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximabU Kopylov, G J Mantzaris, K H Katsanos, et al.
Human Genetics|September 1, 2018
Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel diseaseE R Schiff, M Frampton, N Ben-Yosef, et al.
Pageof 8